Clinical and laboratory features in 205 subjects. Clinical characteristics are presented as mean ± SD or number (percentage).
| Characteristics | RA, n = 113 | OA, n = 56 | Controls, n = 36 | p |
|---|---|---|---|---|
| Age, yrs | 54.0 ± 12.1 | 56.5 ± 6.8 | 53.3 ± 8.3 | 0.257 |
| Women | 93 (82.3) | 52 (92.9) | 27 (75.0) | 0.059 |
| Disease duration, mos | 65.3 ± 71.2 | |||
| Disease onset age, yrs | 48.7 ± 12.4 | |||
| DAS28 | 3.6 ± 1.6 | |||
| ESR, mm/h | 28.2 ± 24.9 | |||
| CRP, mg/dl | 0.88 ± 1.67 | |||
| RF positivity | 89/113 (78.8) | |||
| Anti-CCP antibody positivity | 63/88 (71.6) | |||
| Seropositive RA | 95/113 (84.1) | |||
| ERA | 26/113 (23.0) | |||
| EORA | 19/113 (16.8) | |||
| DMARD | ||||
| MTX | 94/113 (83.2) | |||
| LFNM | 37/113 (32.7) | |||
| SSZ | 5/113 (4.4) | |||
| HCQ | 34/113 (30.1) | |||
| Prednisolone | 96/113 (85.0) | |||
| Mean prednisolone dose (mg/day) for last 1 month | 4.2 ± 2.3 | |||
| Anti-TNF agent use | 6/113 (5.3) | |||
| TSS | 37.0 ± 33.9 | |||
| TSS, erosion | 9.1 ± 11.5 | |||
| TSS, joint space narrowing | 27.8 ± 24.6 | |||
| BMD | ||||
| Osteoporosis | 18/62 (29.0) | |||
| Non-osteoporosis | 44/62 (71.0) | |||
| BMD (g/cm2) | ||||
| Lumbar | 0.89 ± 0.19 | |||
| Femur, neck | 0.67 ± 0.17 | |||
| Femur, trochanter | 0.59 ± 0.14 | |||
| Femur, upper neck | 0.90 ± 0.18 | |||
| BMD, T score | ||||
| Lumbar | −1.26 ± 1.44 | |||
| Femur, neck | −1.58 ± 1.24 | |||
| Femur, trochanter | −0.81 ± 1.18 | |||
| Femur, upper neck | −0.78 ± 1.23 |
RA: rheumatoid arthritis; OA: osteoarthritis; DAS28: Disease Activity Score 28; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibody; ERA: early rheumatoid arthritis; EORA: elderly onset rheumatoid arthritis; MTX: methotrexate; LFNM: leflunomide; SSZ: sulfasalazine; HCQ: hydroxychloroquine; anti-TNF: anti-tumor necrosis factor; TSS: total Sharp score; BMD: bone mineral density.